Abstract: The invention relates to compositions and methods for enhancing bone healing, bone formation and wound healing. More specifically, it relates to the use of cyclooxygenase 2 (COX-2) following bone fracture, orthopaedic procedure or wound infliction to enhance healing.
Type:
Grant
Filed:
September 11, 2001
Date of Patent:
September 15, 2009
Assignee:
University of Medicine and Dentistry of New Jersey
Abstract: Methods and compositions for modulating cell surface protein expression are provided. The compositions of the present invention are gene constructs comprising ATP-binding cassette transmembrane reporter proteins.
Abstract: Disclosed are hydrophilic choline/N-heterocycle ester compounds containing single amino acids, peptides, or derivatives thereof which have the potential to express anti-oxidant activity capable of reducing reactive oxygen species in cells. These compounds may be used to inhibit oxidative stress-induced cell injury or death both in vivo and ex vivo. In addition, methods for the synthesis of these compounds are disclosed.
Type:
Grant
Filed:
November 26, 2004
Date of Patent:
September 8, 2009
Assignee:
University of Rochester
Inventors:
Shey-Shing Sheu, Marion W. Anders, Lin Xu, Virendra K. Sharma
Abstract: The present invention provides a dispensing device used for the slow controlled dispensing and diffusion of gels and thickened liquids. More particularly, the present invention relates to wick type air freshening devices, which employ a wick to convey materials from an enclosed container by capillary action.
Type:
Grant
Filed:
December 16, 2003
Date of Patent:
September 8, 2009
Assignee:
International Flavors & Fragrances, Inc.
Abstract: The present invention is a transgenic non-human animal whose genome contains a transgene containing a nucleic acid encoding a cyclin E protein operably linked to a regulatory element including a lung-specific promoter. The transgenic animals of the present invention have elevated levels cyclin E protein in the lung and have in increased occurrence of lung carcinogenesis. The animals of the instant invention were also found to have increased levels of Gli1 and Shh. Vectors, cells and cell lines are provided, as is a method for identifying a therapeutic agent for the chemoprevention or treatment of lung cancer.
Type:
Grant
Filed:
July 28, 2006
Date of Patent:
September 8, 2009
Assignee:
Trustees of Dartmouth College
Inventors:
Ethan Dmitrovsky, Yan Ma, Sarah J. Freemantle
Abstract: The invention relates to methods for identifying the sequence of one or more variant nucleotides in nucleic acid molecules. The method involves cleaving a double-stranded nucleic acid molecule containing a mismatch with a mismatch-specific endonuclease which cleaves on the 3? side of the mismatch, and preserving the integrity of the variant nucleotide by ligating a Double-Stranded Linker with a degenerate 3?-overhang to said variant nucleotide. Because the variant nucleotide is immediately adjacent to the linker, PCR and/or sequence-by-synthesis analysis can be readily carried out.
Type:
Grant
Filed:
April 11, 2008
Date of Patent:
August 25, 2009
Assignee:
Transgenomic, Inc.
Inventors:
Paul D. Taylor, Reyes Candau, Gary F. Gerard
Abstract: The present invention relates to isolated nucleic acid sequences encoding CEL II endonuclease and vectors and host cells for producing a protein encoded thereby.
Type:
Grant
Filed:
May 18, 2005
Date of Patent:
July 14, 2009
Assignee:
Transgenomic, Inc.
Inventors:
Harini Shandilya, Gary F. Gerard, Peter Qiu
Abstract: This invention relates to a method for assessing risk of prostate and/or ovarian cancer. Specifically, in one embodiment it relates to utilizing both Cln101 and Prostate Specific Antigen (PSA) in combination to determine the risk of prostate cancer. In an alternative embodiment, the invention is relates to utilizing Cln101 alone or in combination with CA125 to determine the risk of ovarian cancer. The invention further provides isolated anti-prostate or ovarian cancer antigen (Cln101) antibodies that bind to Cln101 in vivo. The invention also encompasses compositions comprising an anti-Cln101 antibody and a carrier. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-Cln101 antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-Cln101 antibodies. The invention encompasses a method of producing the anti-Cln10I antibodies.
Type:
Grant
Filed:
June 1, 2004
Date of Patent:
July 14, 2009
Assignee:
diaDexus, Inc.
Inventors:
Xiaozhu Duan, Nam Kim, Robert L. Wolfert
Abstract: Methods, systems and kits are provided for detecting and quantifying multiple immunogens in a sample via consecutive addition of quantifiable extenders to immunogen bound complexes of immunogen binding agent attached to a DNA containing an RNA polymerase promoter.
Type:
Grant
Filed:
July 28, 2006
Date of Patent:
June 23, 2009
Assignee:
Trustees of the University of Pennsylvania
Abstract: A novel class of thermal hysteresis (antifreeze) proteins (THP) that have up to 100 times the specific activity of fish antifreeze proteins has been isolated and purified from the mealworm beetle, Tenebrio molitor. Internal sequencing of the proteins, leading to cDNA cloning and production of the protein in bacteria has confirmed the identity and activity of the 8.4 to 10.7 kDa THP. They are novel Thr- and Cys-rich proteins composed largely of 12-amino-acid repeats of cys-thr-xaa-ser-xaa-xaa-cys-xaa-xaa-ala-xaa-thr. At a concentration of 55 ?g/mL, the THP depressed the freezing point 1.6° C. below the melting point, and at a concentration of ˜1 mg/mL the THP or its variants can account for the 5.5° C. of thermal hysteresis found in Tenebrio larvae. The THP function by an adsorption-inhibition mechanism and produce oval-shaped ice crystals with curved prism faces.
Type:
Grant
Filed:
June 4, 2004
Date of Patent:
May 12, 2009
Assignee:
Queen's University at Kingston
Inventors:
Laurie A. Graham, Yih-Cherng Liou, Virginia K. Walker, Peter L. Davies
Abstract: Methods for culturing human lung mast cells in the absence of co-culture with feeder cells which are viable for longer than 4 days are provided. Also provided are methods for using these human lung mast cell cultures to assess biological and pharmacological activities of these cells in vivo and to identify modulators of the survival, proliferation, function and phenotypic expression of human lung mast cells. Modulators identified via these cells are useful in the prevention and treatment of diseases involving human lung mast cell function.
Type:
Grant
Filed:
August 8, 2001
Date of Patent:
April 28, 2009
Assignee:
Philadelphia, Health and Education Corporation
Abstract: A method for isolating human neuroepithelial precursor cells from human fetal tissue by culturing the human fetal cells in fibroblast growth factor and chick embryo extract and immunodepleting from the cultured human fetal cells any cells expressing A2B5, NG2 and eNCAM is provided. In addition, methods for transplanting these cells into an animal are provided. Animals models transplanted with these human neuroepithelial precursor cells and methods for monitoring survival, proliferation, differentiation and migration of the cells in the animal model via detection of human specific markers are also provided.
Type:
Grant
Filed:
January 14, 2005
Date of Patent:
April 14, 2009
Assignee:
University of Utah Research Foundation
Inventors:
Margot Mayer-Proschel, Mahendra S. Rao, Patrick A. Tresco, Darin J. Messina
Abstract: A novel imidazolium compound represented by the following general formula (I), which has an allyl group incorporated in the 3-position of the imidazolium ring. It needs no complicated operations for dissolution and has excellent handleability and a high ionic conductivity.
Type:
Grant
Filed:
February 24, 2005
Date of Patent:
April 14, 2009
Assignee:
Kanto Kagaku Kabushiki Kaisha
Inventors:
Hiroyuki Ohno, Tomonobu Mizumo, Masahiro Yoshida, Takayoshi Suga
Abstract: The present invention is a method distinguishing between head and neck squamous cell carcinoma and lung squamous cell carcinoma. In particular, a 10-gene classifier has been identified which can be used to distinguish between primary squamous cell carcinoma of the lung and metastatic head and neck squamous cell carcinoma. These genes include CXCL13, COL6A2, SFTPB, KRT14, TSPYL5, TMP3, KLK10, MMP1, GAS1, and MYH2. A panel of one or more of these genes, or proteins encoded thereby, can be used for early diagnosis and selection of an appropriate therapeutic treatment.
Type:
Grant
Filed:
November 16, 2006
Date of Patent:
April 7, 2009
Assignees:
The Wistar Institute, Trustees of the University of Pennsylvania
Inventors:
Louise C. Showe, Michael Nebozhyn, Anil Vachani, Steven M. Albelda
Abstract: The present invention relates to methods and compositions pertaining to conjugates composed of a peptide nucleic acid (PNA) moiety and a neamine derivative moiety. Methods for using such conjugates for modulating the activity of a target nucleic acid molecule and for preventing or treating a disease associated with an aberrant nucleic acid molecule are also provided.
Type:
Grant
Filed:
December 6, 2004
Date of Patent:
April 7, 2009
Assignee:
University of Medicine & Dentistry of New Jersey
Inventors:
Jean-Luc Decout, Virendra N. Pandey, Emmanuel Riguet
Abstract: The present invention relates to the specific inhibition of matrix metalloproteinase 1 (MMP-1) using agents which inhibit the synthesis or expression of MMP-1. Such agents are useful for suppressing invasion or metastasis of a tumor cell and in the treatment, prevention and management of cancer.
Abstract: Recombinant plasminogen activator inhibitor-1 (PAI-1) isoforms which lack the reactive center loop and contain the complete heparin-binding domain or lack at least a portion of the heparin-binding domain are described. The rPAI-1 isoforms disclosed herein may be used to modulate angiogenesis through blocking release of VEGF from a VEGF-heparin complex. Furthermore, the rPAI-1 proteins may be used to inhibit cell proliferation and migration, induce apoptosis, and produce proteolytic fragments corresponding to angiostatin kringles 1-3 and kringles 1-4. A truncated proteolytic plasmin protein of 34 kDa is also provided.
Type:
Grant
Filed:
January 30, 2007
Date of Patent:
March 31, 2009
Assignee:
Trustees of Dartmouth College
Inventors:
Mary Jo Mulligan-Kehoe, Richard J. Powell
Abstract: A method for cleaning a semiconductor substrate having a contact angle between the surface thereof and water dropped thereon of at least 70 degrees comprises contacting the semiconductor surface with a cleaning liquid composition including an aliphatic polycarboxylic acid, an organic solvent having a hydroxyl group and/or an ether group, an anionic surfactant and water.
Abstract: The invention relates to oligonucleotide agents that inhibit RNase H activity of a retroid virus reverse transcriptase and are useful for inhibiting retroid virus proliferation and preventing or treating a retroid virus infection.
Type:
Grant
Filed:
December 30, 2003
Date of Patent:
March 10, 2009
Assignee:
McGill University
Inventors:
Masad J. Damha, Rami N. Hannoush, Kyung-Lyum Min, Sandra Carriero